Keyphrases
Chemotherapy
100%
Chronic Lymphocytic Leukemia
93%
Acute Myeloid Leukemia
79%
Leukemia Patients
78%
Leukemia
77%
Acute Leukemia
74%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
72%
Chronic Myeloid Leukemia
70%
Acute Lymphoblastic Leukemia
69%
Hodgkin Disease
66%
Non-Hodgkin Lymphoma
64%
Meta-analysis
58%
Systematic Meta-analysis
49%
T Cells
46%
Hematological Malignancies
42%
Lymphoma
42%
Remission
41%
Burkitt Lymphoma
41%
Complete Remission
41%
High Risk
41%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
40%
Interferon-α (IFN-α)
39%
Stem Cell Transplantation
39%
Lymphocytes
38%
Israel
37%
Relative Risk
37%
Multiple Myeloma
34%
SHEBA
34%
Rituximab
33%
Medical Center
32%
Clonal Evolution
32%
Tumor
32%
Malignancy
31%
Reduced-intensity Conditioning
31%
Acute Promyelocytic Leukemia
31%
Overall Survival
30%
Imatinib
30%
Combination Chemotherapy
30%
Confidence Interval
28%
High Dose
27%
Radiotherapy
26%
Bone Marrow Transplantation
25%
Red Cells
25%
Leukemic Cells
25%
Fluorescence in Situ Hybridization
24%
Bone Marrow
24%
Aplastic Anemia
23%
Gaza Strip
23%
Environmental Factors
23%
Treatment Results
23%
Medicine and Dentistry
Disease
99%
Acute Lymphoblastic Leukemia
88%
Hodgkin's Lymphoma
84%
Acute Leukemia
65%
Non-Hodgkin Lymphoma
61%
Leukemia
60%
Acute Myeloid Leukemia
54%
B-Cell Chronic Lymphocytic Leukemia
50%
Lymphocyte
48%
Meta-Analysis
35%
Infection
35%
Chronic Myelogenous Leukemia
34%
Radiation Therapy
33%
Burkitt's Lymphoma
32%
Hematologic Malignancy
32%
Reduced Intensity Conditioning
31%
Cancer
30%
T Cell
28%
Lymphoproliferative Disease
27%
Neoplasm
27%
Acute Promyelocytic Leukemia
26%
Positron Emission Tomography-Computed Tomography
26%
Systematic Review
25%
Environmental Factor
25%
Rituximab
25%
Immunoglobulin
24%
Allogeneic Stem Cell Transplantation
24%
Multiple Myeloma
24%
Allogeneic Hematopoietic Stem Cell Transplantation
23%
Interferon
23%
Plasmacytoma
23%
Aplastic Anemia
21%
Pediatrics
21%
Hemolytic Anemia
20%
Adriamycin Bleomycin Vinblastine Dacarbazine
19%
Autologous Stem Cell Transplantation
19%
Busulfan
19%
Immunoglobulin Heavy Chain
19%
Combination Chemotherapy
19%
Tretinoin
19%
Stem Cell Therapy
19%
Overall Survival
18%
Neutropenia
17%
Glucose 6 Phosphate Dehydrogenase
17%
Vincristine
17%
Adverse Event
17%
Platelet
17%
Oncology
15%
Rosette Formation
15%
Ferritin
15%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
65%
Acute Myeloid Leukemia
64%
Chemotherapy
63%
Remission
62%
Nonhodgkin Lymphoma
57%
Leukemia
51%
Acute Leukemia
47%
Chronic Myeloid Leukemia
46%
Infection
41%
Acute Lymphoblastic Leukemia
39%
Vincristine
31%
Hodgkin Disease
31%
Interferon
31%
Imatinib
30%
Hematologic Malignancy
30%
Immunoglobulin
29%
Adverse Event
26%
Rituximab
25%
Chronic Lymphatic Leukemia
25%
Cytarabine
23%
Overall Survival
22%
Doxorubicin
22%
Aplastic Anemia
21%
Bleomycin
21%
Prednisone
21%
Promyelocytic Leukemia
20%
Cyclophosphamide
19%
Multiple Myeloma
17%
Burkitt's Lymphoma
17%
All Cause Mortality
15%
Busulfan
15%
Ibritumomab Tiuxetan
15%
Hemopoietic Growth Factor
15%
Retinoic Acid
15%
Colony Stimulating Factor
15%
Infectious Complication
15%
Disease Free Survival
15%
Procarbazine
14%
Randomized Controlled Trial
13%
Vein Occlusion
12%
Protein Tyrosine Kinase Inhibitor
11%
Hematologic Disease
11%
Thrombocytopenia
11%
Cytokine
11%
Progression Free Survival
10%
Myelodysplastic Syndrome
10%
Lymphoproliferative Disease
10%
Neoplasm
10%
Graft Versus Host Reaction
10%
Hereditary Hemolytic Anemia
9%